SG11201801984TA - Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins - Google Patents
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteinsInfo
- Publication number
- SG11201801984TA SG11201801984TA SG11201801984TA SG11201801984TA SG11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA
- Authority
- SG
- Singapore
- Prior art keywords
- type
- compositions
- methods
- chimeric proteins
- extracellular domains
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235727P | 2015-10-01 | 2015-10-01 | |
US201562263313P | 2015-12-04 | 2015-12-04 | |
US201662372574P | 2016-08-09 | 2016-08-09 | |
PCT/US2016/054598 WO2017059168A1 (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201801984TA true SG11201801984TA (en) | 2018-04-27 |
Family
ID=58424302
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913573UA SG10201913573UA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
SG10201913591SA SG10201913591SA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
SG11201801984TA SG11201801984TA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
SG10201913597VA SG10201913597VA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
SG10201913576RA SG10201913576RA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913573UA SG10201913573UA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
SG10201913591SA SG10201913591SA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913597VA SG10201913597VA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
SG10201913576RA SG10201913576RA (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
Country Status (17)
Country | Link |
---|---|
US (13) | US10183060B2 (ru) |
EP (2) | EP3356393A4 (ru) |
JP (3) | JP6981973B2 (ru) |
KR (1) | KR20180051651A (ru) |
CN (3) | CN116063566A (ru) |
AU (3) | AU2016331076B2 (ru) |
BR (1) | BR112018006578A2 (ru) |
CA (1) | CA2999280A1 (ru) |
HK (1) | HK1258835A1 (ru) |
IL (3) | IL258029B (ru) |
MX (2) | MX2018004022A (ru) |
PH (1) | PH12018500694A1 (ru) |
RU (2) | RU2022102624A (ru) |
SA (1) | SA518391219B1 (ru) |
SG (5) | SG10201913573UA (ru) |
UA (1) | UA126549C2 (ru) |
WO (1) | WO2017059168A1 (ru) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
HRP20230937T1 (hr) | 2017-01-05 | 2023-11-24 | Kahr Medical Ltd. | Pd1-41bbl fuzijski protein i metode korištenja istog |
WO2018127916A1 (en) * | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
AU2018224852A1 (en) * | 2017-02-27 | 2019-07-11 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
EP3585425A4 (en) * | 2017-02-27 | 2020-10-28 | Shattuck Labs, Inc. | PROCESSES FOR THE MANUFACTURE AND USE OF CHEMERICAL PROTEINS BASED ON EXTRACELLULAR DOMAIN |
JP7121029B2 (ja) * | 2017-02-27 | 2022-08-17 | シャタック ラボ,インコーポレイテッド | Csf1rベースのキメラタンパク質 |
BR112019019973A2 (pt) * | 2017-03-24 | 2020-04-28 | Orpheus Bioscience Inc | pantlds para tratamento de transtornos autoimunes |
KR20180120893A (ko) * | 2017-04-28 | 2018-11-07 | 재단법인 목암생명과학연구소 | Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도 |
EP3658165A4 (en) * | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | ONCOLYTIC VIRUS VECTORS AND USES THEREOF |
CN109646678A (zh) * | 2017-10-12 | 2019-04-19 | 中国科学院上海生命科学研究院 | Sun2蛋白、其制药用途及药物 |
CN108384795A (zh) * | 2017-10-13 | 2018-08-10 | 江苏西迪尔生物技术有限公司 | 作用于tme免疫效应细胞的人工合成基因及验证方法和应用 |
CN117106096A (zh) * | 2017-10-26 | 2023-11-24 | 盛禾(中国)生物制药有限公司 | 新的重组融合蛋白及其制备和用途 |
CN111601823A (zh) * | 2017-11-07 | 2020-08-28 | 德克萨斯大学体系董事会 | 用car-t或car-nk细胞在癌症治疗中靶向lilrb4 |
US20200407401A1 (en) * | 2018-01-04 | 2020-12-31 | Washington University | Compositions and methods for inhibition of alphavirus infection |
CN111971297A (zh) * | 2018-05-16 | 2020-11-20 | 韩国亿诺生物有限公司 | 包含lrit2抑制剂作为活性成分用于预防或治疗癌症的药物组合物 |
EP3796977A4 (en) * | 2018-05-17 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT |
MX2020014031A (es) * | 2018-06-21 | 2021-05-12 | Shattuck Labs Inc | Proteinas heterodimericas y usos de las mismas. |
JP2021531265A (ja) * | 2018-07-11 | 2021-11-18 | カール メディカル リミテッド | Pd1−4−1bblバリアント融合タンパク質及びその使用方法 |
EP3814385A4 (en) | 2018-07-11 | 2022-04-06 | KAHR Medical Ltd. | SIRPALPHA-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
CN112638944A (zh) | 2018-08-23 | 2021-04-09 | 西进公司 | 抗tigit抗体 |
WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
JP2022512541A (ja) * | 2018-08-29 | 2022-02-07 | シャタック ラボ,インコーポレイテッド | Pd-1系キメラタンパク質を含む併用療法 |
AU2019333175A1 (en) * | 2018-08-29 | 2021-03-04 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
MX2021002286A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion. |
US20210179689A1 (en) * | 2018-08-29 | 2021-06-17 | Shattuck Labs, Inc. | Combination therapies comprising tim-3-based chimeric proteins |
CN109053902B (zh) * | 2018-09-11 | 2021-06-15 | 河南科技大学 | 一种嵌合蛋白aqp4-ch2、制备及其应用 |
EP3893888A4 (en) * | 2018-12-10 | 2022-08-31 | Bioxcel Therapeutics, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES USING AN INTERNAL IMMUNITY MODIFIER AND AN OX40 AGONIST |
AU2019406453A1 (en) * | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional molecule directed against human PD-1 |
JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体carにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
US11098093B2 (en) * | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
JP2022516964A (ja) * | 2019-01-07 | 2022-03-03 | シャタック ラボ,インコーポレイテッド | ガンマデルタt細胞を調節するためのヘテロ二量体タンパク質 |
CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
CN113747947A (zh) * | 2019-02-28 | 2021-12-03 | 沙塔克实验室有限公司 | 组合疗法 |
AU2020276296A1 (en) * | 2019-05-16 | 2021-11-11 | Shattuck Labs, Inc. | NK cell-directed chimeric proteins |
CN114585377A (zh) * | 2019-06-21 | 2022-06-03 | 沙塔克实验室有限公司 | 表达嵌合蛋白的t细胞 |
AU2020311636A1 (en) * | 2019-07-11 | 2022-03-03 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
WO2021041958A1 (en) * | 2019-08-30 | 2021-03-04 | Shattuck Labs. Inc. | Chimeric proteins in autoimmunity |
CN112480237B (zh) * | 2019-09-12 | 2023-10-17 | 上海津曼特生物科技有限公司 | 一种融合蛋白及其制备方法和应用 |
CN110592172B (zh) * | 2019-10-29 | 2021-05-28 | 华中农业大学 | 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点 |
CN110964119A (zh) * | 2019-12-05 | 2020-04-07 | 沣潮医药科技(上海)有限公司 | 抗疟二聚体免疫粘附素、药物组合物和用途 |
US20210230248A1 (en) * | 2020-01-25 | 2021-07-29 | Jun Chen | Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof |
CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
CN111849913B (zh) * | 2020-07-31 | 2021-05-25 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
CN116801897A (zh) * | 2020-10-26 | 2023-09-22 | 沙塔克实验室有限公司 | 包含嗜乳脂蛋白的同二聚体和异二聚体蛋白 |
WO2022186521A1 (ko) * | 2021-03-02 | 2022-09-09 | 주식회사 이뮤노로지컬디자이닝랩 | Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
KR20230166089A (ko) * | 2021-03-05 | 2023-12-06 | 샤턱 랩스 인코포레이티드 | Sirp 알파-기반 키메라 단백질을 이용하는 병용 요법 |
WO2022187583A1 (en) * | 2021-03-05 | 2022-09-09 | Shattuck Labs, Inc. | Combination therapies with tim-3-based chimeric proteins |
KR20220138909A (ko) * | 2021-04-06 | 2022-10-14 | 주식회사 이뮤노로지컬디자이닝랩 | Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
WO2023004424A2 (en) * | 2021-07-23 | 2023-01-26 | University Of Southern California | Genetically engineered multifunctional exosomes for immunotherapy |
WO2023019251A1 (en) * | 2021-08-12 | 2023-02-16 | Baylor College Of Medicine | Engineered soluble decoy receptors to enhance cancer immunotherapy |
WO2023119295A1 (en) * | 2021-12-23 | 2023-06-29 | Kahr Medical Ltd. | Lilrb polypeptides and uses thereof |
WO2023141106A2 (en) * | 2022-01-20 | 2023-07-27 | Exocure Biosciences Inc. | Recombinant cell line expressing membrane proteins and vesicles prepared therefrom |
WO2024006931A1 (en) * | 2022-07-01 | 2024-01-04 | Fate Therapeutics, Inc. | Enhancing effector cell durability and efficacy in adoptive cell therapies |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
CA2135644C (en) | 1992-05-14 | 2009-01-27 | Elisabetta Vegeto | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
WO1994026290A1 (en) * | 1993-05-07 | 1994-11-24 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE69632235T2 (de) | 1995-10-18 | 2004-08-26 | Akzo Nobel N.V. | Newcastle-Krankheitsvirus-Kombinationsimpfstoff |
US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
CA2395945C (en) | 2000-01-03 | 2013-12-24 | Tr Associates, L.L.C. | Novel chimeric proteins and methods for using the same |
US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
JP4488740B2 (ja) * | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
AU2003303082B2 (en) * | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
WO2005033144A2 (en) * | 2003-10-03 | 2005-04-14 | Brigham And Women's Hospital | Tim-3 polypeptides |
JP4870569B2 (ja) * | 2003-11-13 | 2012-02-08 | ハンミ ホールディングス カンパニー リミテッド | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
AU2005249570B2 (en) * | 2004-06-04 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat autoinflammatory disease |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
EP2027151A2 (en) | 2006-05-15 | 2009-02-25 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
AU2007260991A1 (en) * | 2006-06-21 | 2007-12-27 | Genentech, Inc. | Crystal structure of OX40L and OX40L complexed with OX40 receptor |
US20100150931A1 (en) * | 2006-11-22 | 2010-06-17 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
DK3056514T3 (da) | 2008-01-15 | 2019-07-01 | Univ Leland Stanford Junior | Fremgangsmåder til at manipulere fagocytose medieret af cd47 |
US20090226435A1 (en) * | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
CA3179151A1 (en) * | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
AU2009269141B2 (en) | 2008-06-30 | 2013-04-04 | University Of Pennsylvania | Fn14/TRAIL fusion proteins |
JP2011526794A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | TGF−βアンタゴニスト多重標的結合性分子 |
DK2344540T3 (da) * | 2008-10-02 | 2018-01-29 | Aptevo Res & Development Llc | Cd86-antagonist multimål bindingsproteiner |
WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
EA201100947A1 (ru) * | 2008-12-19 | 2012-02-28 | Новартис Аг | Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений |
ES2609333T3 (es) | 2009-03-13 | 2017-04-19 | The Trustees of The University of Pennsylvania-Center for Technology Transfer | Proteínas de fusión OX40/TRAIL |
JP6066732B2 (ja) * | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
ES2876421T3 (es) * | 2011-04-13 | 2021-11-12 | Bristol Myers Squibb Co | Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos |
US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术(上海)有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
CN107266584B (zh) | 2011-07-29 | 2022-05-13 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
CA3004695C (en) * | 2012-04-30 | 2020-08-04 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
PT2850106T (pt) | 2012-05-18 | 2022-07-18 | Aptevo Res & Development Llc | Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 |
US20140056890A1 (en) | 2012-06-06 | 2014-02-27 | Oncomed Pharmaceuticals, Inc. | Binding Agents That Modulate the Hippo Pathway and Uses Thereof |
CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
DK2931752T3 (da) | 2012-12-17 | 2019-11-18 | Trillium Therapeutics Inc | Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner |
EP2941438A1 (en) | 2013-01-01 | 2015-11-11 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
US9873747B2 (en) | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
EP2950814A4 (en) | 2013-01-31 | 2016-06-08 | Univ Jefferson | PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF |
CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
CA2902830C (en) | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
ES2792183T3 (es) * | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
KR20160065925A (ko) * | 2013-10-15 | 2016-06-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 응고 인자 vii 폴리펩티드 |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
WO2015095410A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
EP3527587A1 (en) * | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists |
US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
CA2936244A1 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
KR102314088B1 (ko) * | 2014-03-24 | 2021-10-15 | 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 | 새로운 이중 기능성의 재조합 융합 단백질, 이의 제조 방법 및 용도 |
WO2015183902A1 (en) | 2014-05-29 | 2015-12-03 | Medimmune, Llc | Ox40l fusion proteins and uses thereof |
EP3160497A4 (en) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
TWI759810B (zh) | 2014-08-08 | 2022-04-01 | 美商Alx腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
NZ728175A (en) | 2014-08-11 | 2023-03-31 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
ES2751915T5 (es) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
EP3250601A4 (en) * | 2015-01-26 | 2018-07-11 | MacroGenics, Inc. | Multivalent molecules comprising dr5-binding domains |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
WO2016127015A1 (en) | 2015-02-06 | 2016-08-11 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
CN114425077A (zh) | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
CN108350048B (zh) | 2015-08-07 | 2024-02-09 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
-
2016
- 2016-09-30 RU RU2022102624A patent/RU2022102624A/ru unknown
- 2016-09-30 AU AU2016331076A patent/AU2016331076B2/en active Active
- 2016-09-30 SG SG10201913573UA patent/SG10201913573UA/en unknown
- 2016-09-30 CN CN202211295685.8A patent/CN116063566A/zh active Pending
- 2016-09-30 BR BR112018006578-1A patent/BR112018006578A2/pt active Search and Examination
- 2016-09-30 CN CN201680001952.2A patent/CN108350055B/zh active Active
- 2016-09-30 UA UAA201802923A patent/UA126549C2/uk unknown
- 2016-09-30 IL IL258029A patent/IL258029B/en unknown
- 2016-09-30 MX MX2018004022A patent/MX2018004022A/es unknown
- 2016-09-30 CA CA2999280A patent/CA2999280A1/en active Pending
- 2016-09-30 SG SG10201913591SA patent/SG10201913591SA/en unknown
- 2016-09-30 KR KR1020187012378A patent/KR20180051651A/ko not_active Application Discontinuation
- 2016-09-30 US US15/281,196 patent/US10183060B2/en active Active
- 2016-09-30 RU RU2018111119A patent/RU2766200C1/ru active
- 2016-09-30 IL IL303586A patent/IL303586A/en unknown
- 2016-09-30 EP EP16852655.6A patent/EP3356393A4/en active Pending
- 2016-09-30 IL IL295423A patent/IL295423B2/en unknown
- 2016-09-30 JP JP2018517183A patent/JP6981973B2/ja active Active
- 2016-09-30 SG SG11201801984TA patent/SG11201801984TA/en unknown
- 2016-09-30 SG SG10201913597VA patent/SG10201913597VA/en unknown
- 2016-09-30 SG SG10201913576RA patent/SG10201913576RA/en unknown
- 2016-09-30 CN CN202211295776.1A patent/CN116063567A/zh active Pending
- 2016-09-30 EP EP22199596.2A patent/EP4183451A1/en active Pending
- 2016-09-30 WO PCT/US2016/054598 patent/WO2017059168A1/en active Application Filing
-
2017
- 2017-11-06 US US15/804,533 patent/US10086042B2/en active Active
- 2017-12-22 US US15/853,241 patent/US10188701B2/en active Active
-
2018
- 2018-03-27 PH PH12018500694A patent/PH12018500694A1/en unknown
- 2018-03-28 MX MX2022001299A patent/MX2022001299A/es unknown
- 2018-03-28 SA SA518391219A patent/SA518391219B1/ar unknown
- 2018-06-29 US US16/024,209 patent/US10449233B2/en active Active
- 2018-06-29 US US16/024,226 patent/US10493128B2/en active Active
- 2018-06-29 US US16/024,218 patent/US10660936B2/en active Active
- 2018-06-29 US US16/024,228 patent/US10525102B2/en active Active
- 2018-06-29 US US16/024,214 patent/US10646545B2/en active Active
- 2018-11-28 US US16/203,469 patent/US10543253B2/en active Active
-
2019
- 2019-01-25 HK HK19101303.9A patent/HK1258835A1/zh unknown
- 2019-11-08 US US16/678,382 patent/US10653748B2/en active Active
-
2020
- 2020-03-09 US US16/813,165 patent/US20200246431A1/en active Pending
- 2020-04-08 US US16/843,029 patent/US11654180B2/en active Active
-
2021
- 2021-01-20 AU AU2021200367A patent/AU2021200367C1/en active Active
- 2021-08-02 JP JP2021126595A patent/JP7303254B2/ja active Active
- 2021-09-20 US US17/479,776 patent/US11547742B1/en active Active
-
2023
- 2023-06-22 JP JP2023102740A patent/JP2023112132A/ja active Pending
-
2024
- 2024-04-08 AU AU2024202253A patent/AU2024202253A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258835A1 (zh) | 作為異源嵌合蛋白鄰接i型和ii型胞外結構域的組合物和方法 | |
HK1259190A1 (zh) | 嵌合抗原受體相關的方法和組合物 | |
IL282168A (en) | Factor VIII chimeric proteins and their uses | |
HK1252643A1 (zh) | 使用融合蛋白對tcr重編程的組合物和方法 | |
ZA201704231B (en) | Chimeric protein | |
HK1253306A1 (zh) | 抗ntb-a抗體及相關組合物和方法 | |
SI3240895T1 (sl) | Sestavki in postopki za glikozilacijo proteinov | |
GB201709537D0 (en) | Fusion protein comprising three binding domains to 5ta and cd3 | |
SG11201704010UA (en) | Fibroin-derived protein composition | |
IL247632A0 (en) | Methods and compositions for the secretion of heterologous polypeptides | |
EP3256163A4 (en) | Methods and compositions for modulating lilr proteins | |
IL257302B (en) | apoa-1 fusion polypeptides and related compositions and methods | |
HK1243107B (zh) | 嵌合蛋白 |